STRO-002, an investigational antibody-drug conjugate, continues to show promising safety and anti-tumor activity in women with advanced ovarian cancer, according to preliminary data from a Phase 1 clinical trial. The findings were presented by Wendel Naumann, MD, principal investigator of the trial, in a recent virtual presentation at the American Association for Cancer Research (AACR)…
Category: <span>Blog</span>
FDA Approves Darzalex Faspro as Injection Therapy for Multiple Myeloma
The U.S. Food and Drug Administration (FDA) approved Janssen‘s new formulation of daratumumab — a subcutaneous or under-the-skin injection treatment called Darzalex Faspro (daratumumab and hyaluronidase) — as a faster and easier alternative for people with multiple myeloma. The original formulation, Darzalex, requires an intravenous (into-the-vein) infusion given over several hours. Darzalex Faspro is seen to be an equally…
Dostarlimab Shows Promise for Advanced Endometrial Cancer, Early Trial Results Show
A subset of women with recurrent or advanced endometrial cancer, whose disease progressed on or after platinum-based chemotherapy, achieved clinically meaningful responses after treatment with dostarlimab, results of a Phase 1 clinical trial show. The findings, “Safety and efficacy of the anti–PD-1 monoclonal antibody dostarlimab in patients with recurrent or advanced dMMR endometrial cancer,” were…
Actemra May Treat Severe COVID-19 Infections in Myeloma Patients, Case Report Suggests
Actemra (tocilizumab), a medicine approved for certain types of arthritis, may be effective in treating severe infections with the new coronavirus in people with multiple myeloma or other blood disorders, findings from a patient in China suggest. The case report also indicates that those with blood cancers may have atypical COVID-19 symptoms, like an absence…
Cirmtuzumab-Imbruvica Yields ‘Encouraging’ Response Rates Against Mantle Cell Lymphoma, Ongoing Trial Shows
Combination therapy with the investigational treatment cirmtuzumab plus Imbruvica (ibrutinib) led to “highly encouraging” response rates among patients with mantle cell lymphoma (MCL), a type of B-cell cancer, according to the latest clinical results announced by Oncternal Therapeutics. Cirmtuzumab, developed by Oncternal, is an investigational antibody that blocks ROR1, or receptor tyrosine kinase-like orphan receptor 1.…
Large Study Finds No Evidence That Low-dose Aspirin Reduces Alzheimer’s Risk
Taking daily low-dose aspirin does not seem to reduce the risk of dementia, cognitive decline, or Alzheimer’s disease, new clinical trial data show. The results were published in Neurology in a study, titled “Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline.” Aspirin is a widely-used anti-inflammatory medication. Among its uses, low-dose daily…
FDA Approves Zejula as First-line Maintenance Therapy for Advanced Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has approved Zejula (niraparib) as a first-line maintenance therapy for women with advanced ovarian cancer who responded to platinum-based chemotherapy, regardless of their BRCA mutation status. This indication also includes patients with advanced fallopian tube or primary peritoneal cancer. The decision comes two months after FDA’s acceptance of a supplemental New Drug Application (sNDA), which…
Enhertu Approved for HER2-Positive Inoperable or Metastatic Cancer in Japan
Enhertu (trastuzumab deruxtecan) has been approved in Japan to treat adults with HER2-positive inoperable or metastatic breast cancer that is resistant to chemotherapy, or those who cannot tolerate it. Enhertu is an antibody-drug conjugate (ADC) made up of the anti-HER2 antibody trastuzumab bound to the cancer-killing compound deruxtecan (a derivative of exatecan). HER2 is a protein found…
Ovarian Cancer Often More Advanced at Diagnosis in Rural Areas in US
Women living in rural areas in the U.S. are significantly more likely to have metastatic disease at the time of their ovarian cancer diagnosis than those living in metropolitan areas, a study of patients in three Midwest states found. This finding is likely not a consequence of travel time to reach a primary care provider.…
Industry leaders seek to advance innovative resources for rare and orphan disease communities amid COVID-19 outbreak
FFF Enterprises and BioNews announced today that both rare and orphan disease advocates are joining forces to provide patients with resources to help them connect as a community and continue to manage their health during this time when many are finding themselves alone. Recognized as the nation’s leading supplier of critical-care biopharmaceuticals, plasma products and…









